.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Healthtrust
Julphar
Chinese Patent Office
McKinsey
Deloitte
Dow
Queensland Health
Moodys
Novartis

Generated: November 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,947,295

« Back to Dashboard

Which drugs does patent 7,947,295 protect, and when does it expire?


Patent 7,947,295 protects ILEVRO and is included in one NDA. There has been one Paragraph IV challenge on Ilevro.

This patent has thirty-seven patent family members in fifteen countries.

Summary for Patent: 7,947,295

Title:Ophthalmic compositions containing a synergistic combination of two polymers
Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity.
Inventor(s): Chowhan; Masood A. (Arlington, TX), Chen; Huagang (Arlington, TX)
Assignee: Alcon, Inc. (Hunenberg, CH)
Application Number:11/673,070
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis Pharms Corp
ILEVRO
nepafenac
SUSPENSION/DROPS;OPHTHALMIC203491-001Oct 16, 2012RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,947,295

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,709,012Ophthalmic compositions containing a synergistic combination of two polymers► Subscribe
8,313,754Ophthalmic compositions containing a synergistic combination of two polymers► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,947,295

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2839847► Subscribe
Canada2839849► Subscribe
Canada2839898► Subscribe
Canada2839928► Subscribe
Canada2839930► Subscribe
China1802147► Subscribe
China100475192► Subscribe
Cyprus1114252► Subscribe
Denmark2116227► Subscribe
European Patent Office1631257► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Covington
Mallinckrodt
Chubb
US Army
Teva
Express Scripts
Argus Health
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot